Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition
Xingxing Chen,Xue Xia,Tiancheng Dong,Zhiwei Lin,Leilei Du,Hao Zhou
DOI: https://doi.org/10.2147/DDDT.S360283
2022-08-04
Abstract:Xingxing Chen, &ast Xue Xia, &ast Tiancheng Dong, Zhiwei Lin, Leilei Du, Hao Zhou Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hao Zhou, Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, NanBai Xiang Avenue, Ouhai District, Wenzhou, 325000, People's Republic of China, Tel +86 1 396 880 1939, Fax +86 577 555 79796, Email Purpose: Endothelial-to-mesenchymal transition (EndMT) is an important mechanism underlying cardiac fibrosis. The anti-ischemic drug trimetazidine (TMZ) is reportedly useful in ventricular remodeling and associated with NADPH oxidase (NOX) 2. This study aimed to investigate the possible effect of TMZ on cardiac fibrosis exerted via the inhibition of NOX2-mediated EndMT. Methods: A cardiac fibrosis model was established in Sprague-Dawley rats through a subcutaneous injection of isoproterenol (ISO, 5 mg/kg/d). Echocardiographic parameters, myocardial fibrosis, NOX2 expression and EndMT were assessed. An in vitro model of EndMT was developed using human umbilical vein endothelial cells (HUVECs) via treatment with transforming growth factor-β (TGF-β) at 10 ng/mL for 24 h. HUVECs were administrated with TMZ or TMZ and lentivirus, the expression of EndMT and related proteins was observed by wound healing assay, immunoblotting, and immunofluorescence. Results: Rats injected with ISO exhibited severe interstitial cardiac fibrosis and perivascular fibrosis, decreased left ventricular ejection fraction, and increased NOX activity. TMZ treatment mitigated cardiac fibrosis, ameliorated left ventricular dysfunction, and reduced NOX activity. In addition, TMZ effectively inhibited EndMT in ISO-treated rat hearts and TGF-β-treated HUVECs, as manifested by increased CD31 expression, decreased α-SMA expression, and suppressed cell migration. Compared with the control group, the expression of NOX2, nuclear factor-κB (NF-κB), and Snail was increased in vivo and in vitro but decreased with TMZ treatment. Furthermore, the overexpression of NOX2 by lentivirus abolished the protective effects of TMZ on TGF-β-induced EndMT. Conclusion: TMZ may ameliorate EndMT and ISO-induced cardiac fibrosis through the NOX2/NF-κB/Snail pathway. The findings of the study may provide new insights into the potential role of TMZ in the pathophysiology of cardiac fibrosis. Keywords: trimetazidine, endothelial-to-mesenchymal transition, cardiac fibrosis, NADPH oxidase 2 Myocardial fibrosis, characterized as interstitial fibroblast proliferation and excessive collagen deposition, is the structural basis of myocardial stiffness and the key process of cardiac function transformation from the compensatory phase to heart failure. 1 Thus, it is imperative to understand the mechanisms involved in inhibition of myocardial fibrosis. Cardiac fibroblasts are generally the primary effector cells of fibrosis and have been reported to be partly derived from cardiac endothelial cells through the endothelial to mesenchymal transition (EndMT) process. 2 EndMT is a process by which endothelial cells lose a portion of their cellular features and obtain the mesenchymal phenotype, including the loss of tight junctions and increased production of extracellular matrix. Recently, EndMT has been increasingly recognized as a vital process that contributes to various cardiovascular pathologies in adults, which include atherosclerosis, valvular heart disease, cardiac fibrosis, and myocardial infarction. EndMT reportedly promoted cardiac fibrosis, as evidenced by a lineage-tracking quantitative analysis that demonstrated that 27–35% of fibroblasts in cardiac fibrosis tissues are derived from endothelial cells. 2 In the fibrotic hearts of patients with chronic kidney disease, nearly 20% of the fibroblasts were transformed via EndMT. 3 Previous evidence suggests that the progression of cardiac remodeling and ventricular contractile dysfunction in patients with ischemic cardiomyopathy is a consequence of substrate metabolism disorder. 4 Trimetazidine (TMZ) is an anti-anginal agent that reduces the oxidation rate of free fatty acids by inhibiting mitochondrial long-chain 3-ketoacyl CoA thiolase, which stimulates the heart to utilize glucose oxidation for energy supply and optimization of energy metabolism. 5 Standard use of TMZ effectively relieves the clinical symptoms of patients with ischemic heart disease. 6–8 TMZ has also been reported to improve cardiomyocytes' tolerance to hypoxia without affecting the hemodynamics, left ventricular dimensions, and left ventricular ejection frac -Abstract Truncated-